EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitLeitlinieOpen access · CC BY-NC 4.0

Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants

Eunice Stiboy iD, Mei Chan iD, Md Saiful Islam, Gemma L Saravanos iD, Kei Lui, Adam Jaffe, Nusrat Homaira iD

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26324 ↗

At a glance

Übersichtsarbeit in Pediatric Pulmonology, 2023. Written by Eunice Stiboy and 6 co-authors. Institution: School of Public Health, The University of Sydney, Camperdown, Australia. Major MEDLINE topics: Antibodies, Monoclonal, Respiratory Syncytial Virus Infections. Cited 4 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Uniformity and compliance with clinical practice guidelines (CPGs) for use of palivizumab in preventing severe respiratory syncytial viral infection in Australian high‐risk infants remain unclear.

Methods

An online survey was conducted across the Australian and New Zealand Neonatal Network (ANZNN) to determine clinical practices around palivizumab. A literature search was also performed to identify and compare national and international guidelines.

Results

A total of 65 of 422 ANZNN members completed the survey. Respondents included 61 senior medical staff of consultants/staff specialists (78%) and four nursing staff (6%). According to the survey, infants most likely to be recommended palivizumab included preterm infants born

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalRespiratory Syncytial Virus InfectionsChildHumansInfantInfant, NewbornAntibodies, Monoclonal, HumanizedAntiviral AgentsAustraliaHospitalizationInfant, PrematurePalivizumabRespiratory Syncytial VirusesPractice Guidelines as Topic

Author keywords

PalivizumabRSVguidelineinfantsprophylaxis

Substances

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntiviral AgentsPalivizumab

Authors and institutions

  • School of Public Health, The University of Sydney, Camperdown, Australia.
  • UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.
  • National Center for Epidemiology and Population Health, ANU, Canberra, Australia.
  • Chidlren's Hospital Westmead Clinical School, The University of Sydney, Camperdown, Australia.
  • Susan Wakil School of Nursing and Midwifery, The University of Sydney, Camperdown, Australia.
  • Australian and New Zealand Neonatal Network, UNSW, Sydney, Sydney, Australia.

ORCID profiles: Eunice Stiboy, Mei Chan, Gemma L Saravanos, Nusrat Homaira

Cite

APA

Stiboy, E., Chan, M., Islam, M. S., Saravanos, G. L., Lui, K., Jaffe, A., & Homaira, N. (2023). Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26324

Vancouver

Stiboy E, Chan M, Islam MS, Saravanos GL, Lui K, Jaffe A, et al. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26324

BibTeX
@article{Stiboy2023,
  author = {Stiboy, Eunice and Chan, Mei and Islam, Md Saiful and Saravanos, Gemma L and Lui, Kei and Jaffe, Adam and Homaira, Nusrat},
  title = {Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26324}
}
Start for free →